SCHEMBL944720

SCHEMBL944720

CCOc1ccc(C#N)cc1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.53
MAPT P10636 3/20 0.46
HPGD P15428 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
S1PR1 P21453 1/20 0.45
MYC P01106 1/20 0.43
WDR5 P61964 1/20 0.43
AGPAT2 O15120 2/20 0.42
FFAR1 O14842 1/20 0.41
AR P10275 1/20 0.41
PDE5A O76074 1/20 0.40
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 1/20 0.40
HSD17B10 Q99714 2/20 0.39
USP2 O75604 1/20 0.39
PRNP P04156 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5089148 0.88 TRPV4 (0.42) TRPV4MAPTHPGDTDP1L3MBTL1
SCHEMBL10760645 0.86 HPGD (0.41) TRPV4MAPTHPGDTDP1L3MBTL1
SCHEMBL29710928 0.86 TRPV4 (0.56) TRPV4S1PR1AGPAT2ARPDE5A
SCHEMBL12221683 0.85 L3MBTL1 (0.43) TRPV4MAPTHPGDTDP1L3MBTL1
SCHEMBL2037172 0.85 HPGD (0.43) TRPV4MAPTHPGDTDP1L3MBTL1
Acetoacetic Acid SCHEMBL27780098 0.85 FFAR1 (0.46) TRPV4MAPTFFAR1ARALDH1A1
SCHEMBL27938601 0.83 HPGD (0.48) MAPTHPGDTDP1L3MBTL1S1PR1
SCHEMBL1402437 0.83 TRPV4 (0.61) TRPV4MAPTHPGDS1PR1AR
SCHEMBL29886939 0.83 FFAR1 (0.40) TRPV4MAPTHPGDTDP1L3MBTL1
SCHEMBL28833261 0.83 FFAR1 (0.40) TRPV4MAPTHPGDTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12275723-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2025-04-15 US disclosed
US-20250026766-A1 Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors BEIGENE, LTD. (KY) 2025-01-23 US disclosed
US-20240400546-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-12-05 US disclosed
EP-4463456-A1 THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS BeiGene, Ltd. (KY) 2024-11-20 EP disclosed
US-20240300938-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-09-12 US disclosed
CN-118510778-A Thiazolopyridylamide derivatives as inhibitors of DNA polymerase θ 百济神州有限公司 2024-08-16 CN disclosed
US-11970486-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-04-30 US disclosed
US-20240124435-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-04-18 US disclosed
CN-117777121-A Compounds and uses thereof 詹森药业有限公司 2024-03-29 CN disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
EP-1670757-B1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2009-05-06 EP disclosed
EP-1670757-B1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2009-05-06 EP disclosed
WO-2008121558-A1 1, 3-THIAZOL-2 (3H) -YLIDENE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-10-09 WO disclosed
US-20080242654-A1 N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBOTT LABORATORIES (US) 2008-10-02 US disclosed
US-20070066573-A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY 2007-03-22 US disclosed
US-20070066573-A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY 2007-03-22 US disclosed
EP-1670757-A1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2006-06-21 EP disclosed
WO-2005040110-A1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2005-05-06 WO disclosed
WO-2005040110-A1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2005-05-06 WO disclosed
EP-0219143-A1 Synergistic herbicidal compositions and methods of use STAUFFER CHEMICAL COMPANY (US) 1987-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242654-A1 N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants CNR2, CNR1, TRPV1 TRPV4 128/4885MAPT 3129/4885HPGD 918/4885
US-20240124435-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 TRPV4 464/4885MAPT 22/4885HPGD 565/4885
US-20240300938-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 TRPV4 464/4885MAPT 22/4885HPGD 565/4885
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 TRPV4 464/4885MAPT 22/4885HPGD 565/4885
US-20240400546-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 TRPV4 464/4885MAPT 22/4885HPGD 565/4885
US-12275723-B2 Compounds and uses thereof NLN, ACHE, CLN6 TRPV4 464/4885MAPT 22/4885HPGD 565/4885
US-20250026766-A1 Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors POLQ, POLK, POLI TRPV4 4715/4885MAPT 544/4885HPGD 1862/4885
US-20070066573-A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors GRIN1, GRIN3A, GRIK5 TRPV4 2526/4885MAPT 558/4885HPGD 1113/4885
US-11970486-B2 Compounds and uses thereof NLN, ACHE, CLN6 TRPV4 464/4885MAPT 22/4885HPGD 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.